Caplin Point Laboratories Ltd.

NSE: CAPLIPOINT | BSE: 524742 | ISIN: INE475E01026 | Industry: Pharmaceuticals
| Falling Comet
1705.6000 13.50 (0.80%)
NSE Feb 23, 2026 12:39 PM
Volume: 21,449
 

1705.60
0.80%
ICICI Securities Limited
Q1FY21 revenues grew a robust 24.7% YoY to | 240.1 crore. EBITDA margins fell 517 bps YoY to 29.8% due to higher operational costs. Sequential margin improvement (up 483 bps) was on account of better gross margins (one-off impact in Q4FY20) despite higher staff costs due to recently acquired subsidiaries. Subsequently, EBITDA grew 6.3% YoY, 33.1% QoQ to | 71.6 crore. PAT grew 8.6% YoY to | 54.5 crore. Delta vis-a-vis EBITDA...
Number of FII/FPI investors decreased from 190 to 174 in Dec 2025 qtr
More from Caplin Point Laboratories Ltd.
Recommended